1. Home
  2. Issues
  3. Volume 2, Issue 1 (2024)
  4. Bayesian Interim Analysis in Basket Tria ...

The New England Journal of Statistics in Data Science


Bayesian Interim Analysis in Basket Trials
Volume 2, Issue 1 (2024), pp. 54–71
Pub. online: 4 September 2023      Type: Methodology Article      Open accessOpen Access
Area: Cancer Research

1 Department of Statistics, University of Connecticut.
3 Department of Biostatistics, Vir Biotechnology.
2 Department of Biostatistics, Vertex Pharmaceuticals.
Accepted
5 August 2023
Published
4 September 2023

Abstract

Basket trials have captured much attention in oncology research in recent years, as advances in health technology have opened up the possibility of classification of patients at the genomic level. Bayesian methods are particularly prevalent in basket trials as the hierarchical structure is adapted to basket trials to allow for information borrowing. In this article, we extend the Bayesian methods to basket trials with treatment and control arms for continuous endpoints, which are often the cases in clinical trials for rare diseases. To account for the imbalance in the covariates which are potentially strong predictors but not stratified in a randomized trial, our models make adjustments for these covariates, and allow different coefficients across baskets. In addition, comparisons are drawn between two-stage design and one-stage design for the four Bayesian methods. Extensive simulation studies are conducted to examine the empirical performance of all models under consideration. A real data analysis is carried out to further demonstrate the usefulness of the Bayesian methods.

Supplementary material

 Supplementary Material
The Supplementary Material includes the models without covariates supplementary results (Section S.1), sensitivity analysis of MFM (Section S.2), derivation of MFM sampling algorithm formula (Section S.3), and testing treatment difference among baskets for CBHM (Section S.4).

References

[1] 
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R. et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26(10) 1626–1634.
[2] 
Ashley, E. A. (2015). The precision medicine initiative: a new national effort. Jama 313(21) 2119–2120.
[3] 
Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics 17(9) 507–522.
[4] 
Berry, S. M., Broglio, K. R., Groshen, S. and Berry, D. A. (2013). Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials. Clinical Trials 10(5) 720–734.
[5] 
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M. et al. (2011). Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine 364(26) 2507–2516.
[6] 
Chu, Y. and Yuan, Y. (2018). A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clinical Trials 15(2) 149–158.
[7] 
Chu, Y. and Yuan, Y. (2018). BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity. Journal of the Royal Statistical Society: Series C (Applied Statistics) 67(3) 723–740. https://doi.org/10.1111/rssc.12255. MR3787974
[8] 
Cunanan, K. M., Gonen, M., Shen, R., Hyman, D. M., Riely, G. J., Begg, C. B. and Iasonos, A. (2017). Basket trials in oncology: a trade-off between complexity and efficiency. Journal of Clinical Oncology 35(3) 271.
[9] 
Freidlin, B. and Korn, E. L. (2013). Borrowing Information across Subgroups in Phase II Trials: Is It Useful? Borrowing Information across Subgroups. Clinical Cancer Research 19(6) 1326–1334.
[10] 
Geng, J. and Hu, G. (2020). Mixture of finite mixtures model for basket trial. arXiv preprint arXiv:2011.04135.
[11] 
Hirakawa, A., Asano, J., Sato, H. and Teramukai, S. (2018). Master protocol trials in oncology: review and new trial designs. Contemporary Clinical Trials Communications 12 1–8.
[12] 
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J. -Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A. et al. (2015). Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. New England Journal of Medicine 373(8) 726–736.
[13] 
Kaizer, A. M., Koopmeiners, J. S., Kane, M. J., Roychoudhury, S., Hong, D. S. and Hobbs, B. P. (2019). Basket designs: statistical considerations for oncology trials. JCO Precision Oncology 3 1–9.
[14] 
Kumar-Sinha, C. and Chinnaiyan, A. M. (2018). Precision oncology in the age of integrative genomics. Nature Biotechnology 36(1) 46–60.
[15] 
Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T. et al. (2018). Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. Journal of Clinical Oncology 36(24) 2532.
[16] 
Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C. et al. (2015). Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. Journal of Clinical Oncology 33(9) 1000.
[17] 
Mehta, C. R. and Pocock, S. J. (2011). Adaptive increase in sample size when interim results are promising: a practical guide with examples. Statistics in Medicine 30(28) 3267–3284. https://doi.org/10.1002/sim.4102. MR2861612
[18] 
Miller, J. W. and Harrison, M. T. (2018). Mixture models with a prior on the number of components. Journal of the American Statistical Association 113(521) 340–356. https://doi.org/10.1080/01621459.2016.1255636. MR3803469
[19] 
Neal, R. M. (1992). Bayesian mixture modeling. In Maximum Entropy and Bayesian Methods 197–211 Springer.
[20] 
Neal, R. M. (2000). Markov chain sampling methods for Dirichlet process mixture models. Journal of Computational and Graphical Statistics 9(2) 249–265. https://doi.org/10.2307/1390653. MR1823804
[21] 
Neuenschwander, B., Wandel, S., Roychoudhury, S. and Bailey, S. (2016). Robust exchangeability designs for early phase clinical trials with multiple strata. Pharmaceutical Statistics 15(2) 123–134.
[22] 
Oaknin, A., Friedman, C. F., Roman, L. D., D’Souza, A., Brana, I., Bidard, F. -C., Goldman, J., Alvarez, E. A., Boni, V., ElNaggar, A. C. et al. (2020). Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic oncology 159(1) 150–156.
[23] 
Ouma, L. O., Grayling, M. J., Wason, J. M. and Zheng, H. (2022). Bayesian modelling strategies for borrowing of information in randomised basket trials. Journal of the Royal Statistical Society Series C: Applied Statistics 71(5) 2014–2037. https://doi.org/10.1111/rssc.12602. MR4511139
[24] 
Pan, J., Bunn, V., Hupf, B. and Lin, J. (2022). Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses. Journal of Biopharmaceutical Statistics 32(4) 613–626.
[25] 
Park, J. J., Siden, E., Zoratti, M. J., Dron, L., Harari, O., Singer, J., Lester, R. T., Thorlund, K. and Mills, E. J. (2019). Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 20(1) 1–10.
[26] 
Park, J. J., Hsu, G., Siden, E. G., Thorlund, K. and Mills, E. J. (2020). An overview of precision oncology basket and umbrella trials for clinicians. CA: A Cancer Journal for Clinicians 70(2) 125–137.
[27] 
Patel, S. P., Othus, M., Chae, Y. K., Giles, F. J., Hansel, D. E., Singh, P. P., Fontaine, A., Shah, M. H., Kasi, A., Baghdadi, T. A. et al. (2020). A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsIpilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine. Clinical Cancer Research 26(10) 2290–2296.
[28] 
Redig, A. J. and Jänne, P. A. (2015). Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 33(9) 975–977.
[29] 
Redman, M. W. and Allegra, C. J. (2015). The master protocol concept. In Seminars in Oncology 42 724–730. Elsevier.
[30] 
Renfro, L. and Sargent, D. (2017). Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Annals of Oncology 28(1) 34–43.
[31] 
Schuck, R. N., Pacanowski, M., Woodcock, J. and Zineh, I. (2018). Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease. Nature Reviews Drug Discovery 17(2) 79–80.
[32] 
Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10(1) 1–10.
[33] 
Simon, R., Geyer, S., Subramanian, J. and Roychowdhury, S. (2016). The Bayesian basket design for genomic variant-driven phase II trials. In Seminars in Oncology 43 13–18. Elsevier.
[34] 
Sleijfer, S., Bogaerts, J. and Siu, L. L. (2013). Designing transformative clinical trials in the cancer genome era. Journal of Clinical Oncology 31(15) 1834–1841.
[35] 
Tao, J. J., Schram, A. M. and Hyman, D. M. (2018). Basket studies: redefining clinical trials in the era of genome-driven oncology. Annual Review of Medicine 69 319.
[36] 
Thall, P. F., Wathen, J. K., Bekele, B. N., Champlin, R. E., Baker, L. H. and Benjamin, R. S. (2003). Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine 22(5) 763–780.
[37] 
U. S. Food and Drug Administration (2018). U.S. Food And Drug Administration: Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-targeted-therapies-low-frequency-molecular-subsets-disease.
[38] 
U. S. Food and Drug Administration (2018). U.S. Food And Drug Administration: Master Protocols: Efficient Clinical Trial Design Strategies To Expedite Development of Oncology Drugs and Biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and.
[39] 
U. S. Food and Drug Administration (2021). E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical.
[40] 
U. S. Food and Drug Administration (2023). Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products. https://www.fda.gov/media/148910/download.
[41] 
Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W. et al. (2022). Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. The Lancet Oncology 23(1) 53–64.
[42] 
Woodcock, J. and LaVange, L. M. (2017). Master protocols to study multiple therapies, multiple diseases, or both. New England Journal of Medicine 377(1) 62–70.
[43] 
Xu, Y., Müller, P., Tsimberidou, A. M. and Berry, D. (2019). A nonparametric Bayesian basket trial design. Biometrical Journal 61(5) 1160–1174. https://doi.org/10.1002/bimj.201700162. MR4013340
[44] 
Zheng, H. and Wason, J. M. (2022). Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy. Biostatistics 23(1) 120–135. https://doi.org/10.1093/biostatistics/kxaa019. MR4366039
[45] 
Zhou, T. and Ji, Y. (2021). RoBoT: a robust Bayesian hypothesis testing method for basket trials. Biostatistics 22(4) 897–912. https://doi.org/10.1093/biostatistics/kxaa005. MR4325734

Full article PDF XML
Full article PDF XML

Copyright
© 2024 New England Statistical Society
Open access article under the CC BY license.

Keywords
Bayesian hierarchical model Calibrated Bayesian hierarchical model Covariates adjustment Mixture of finite mixtures One-minimum power

Metrics
since December 2021
406

Article info
views

204

Full article
views

215

PDF
downloads

51

XML
downloads


Share


RSS